search
Back to results

Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics

Primary Purpose

Agitation

Status
Recruiting
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Nalbuphine
Dexmedetomidine
normal Saline
Sponsored by
Alexandria University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Agitation

Eligibility Criteria

3 Years - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • ASA physical status I &II
  • scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) under general anesthesia

Exclusion Criteria:

  • history of hypersensitivity to the studied drug,
  • refusal of the legal guardian
  • chronic or acute intake of any sedative or analgesic drugs,
  • Psychological& emotional disorder.
  • Cognitive or developmental disorders.
  • severely agitated child at induction of anesthesia
  • Any neurological condition that would limit the patient's ability to communicate with or understand nursing personnel,
  • Existing contraindications to caudal block such as coagulopathy, local and systemic infection.
  • Failure of the caudal block.

Sites / Locations

  • Alexandria universityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

nalbuphine

dexmedetomedine

saline

Arm Description

0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery

receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery

receive a saline solution 10 min before the end of surgery

Outcomes

Primary Outcome Measures

Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) change
Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) based on crying, facial expression, verbal statements, position of torso, touching of the wound and movement of legs will be used for post-operative pain assessment minimum score: 4 best maximum score: 13 worse
pediatric anesthesia emergence delirium (PAED) scale change
pediatric anesthesia emergence delirium (PAED) scale, scale that define the child's behavior in the recovery room sleeping (best) awake, calm irritable, crying inconsolable crying (worse)

Secondary Outcome Measures

The time of first postoperative analgesic dose
in minutes

Full Information

First Posted
February 19, 2022
Last Updated
April 7, 2022
Sponsor
Alexandria University
search

1. Study Identification

Unique Protocol Identification Number
NCT05273671
Brief Title
Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics
Official Title
Comparison Between Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics During Sevoflurane Anesthesia: Prospective Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2022 (Actual)
Primary Completion Date
June 1, 2022 (Anticipated)
Study Completion Date
June 2, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alexandria University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
the investigators hypothesized that Nalbuphine may be alternative pharmacological agent for prevention of emergence agitation in pediatrics who will be scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) during sevoflurane anesthesia
Detailed Description
SEVOFLURANE is widely used popular inhalational anesthetic to induce and maintain anesthesia in children due to its greater hemodynamic stability, less irritation of the airway and low blood gas solubility coefficient, which causes rapid emergence and recovery from general anesthesia in pediatric anesthesia. [1] However, sevoflurane anesthesia is frequently associated with emergence agitation (EA) in children with incidence ranging up to 80%. [2-5] EA is a complex phenomenon and a variety of explanations have been proposed for its etiology. These include multiple surgical and patient related factors as well as anesthesia related factors such as rapid emergence due to the low blood solubility of sevoflurane.[1,2,6] Despite it is usually self limited; EA is still a considerable side-effect because of the risks of falling, self-injury to the child or to the surgical site, the stress caused to both caregivers and families, moreover, increase the need for continuous monitoring of patients by recovery room staffs and physical restraint of patient.[6] Several medications like propofol, fentanyl, a2-adrenergic receptor agonist and ketamine have been investigated in an attempt to reduce the occurrence and severity of EA, with variable outcomes. [4-11] Dexmedetomidine is an a-2 adrenergic agonist with a larger ratio of a2/a1 activity (1600:1) when compared to clonidine (200:1).The hemodynamic effects of dexmedetomidine are similar to that of clonidine and the effects can vary depending on the dose, rat. [10] Nalbuphine (NAL) is a synthetic opioid agonist antagonist acts on kappa and mu opioid receptor producing analgesia and sedation .One of the advantages of NAL over pure narcotic agonists is inducing minimal respiratory depression, it is considered a safe drug and the large margin of safety make it often used for pediatric patients. It has been shown that the use of nalbuphine carries a lower risk of adverse events like nausea, vomiting, pruritus, constipation, and respiratory depression Our primary outcome: The incidence of post-operative EA Secondary outcome:Time to emergence in minutes Time to extubation in minutes Children's hospital eastern Ontario pain scale. Discharge time (min) The time of first postoperative analgesic dose Possible postoperative side effects. All patients will undergo thorough preoperative evaluation, which include history, physical examination and relevant laboratory investigations. None of the patients will be given any solid food for 6 hours preoperatively but each will be encouraged to take clear fluids until 2 hours before induction of anesthesia. All patients will be pre-medicated with 0.3 mg/kg oral midazolam (maximum dose of 12 mg) 30 min before induction. Upon arrival at the operating room, patients will be monitored by non-invasive the blood pressure, temperature, electrocardiogram capnography and pulse oximetry. Inhalation induction will be done via transparent face mask after saturating the breathing system (Jackson-Rees modification of Ayer's T-piece) with a mixture of sevoflurane 8 vol % in 100% O2 (6 L/min). After loss of consciousness, intravenous line will be inserted and Rocuronium 0.6 mg/kg is administered and when adequate depth of anesthesia is reached, a laryngeal mask airway (LMA) of appropriate size for the age and weight of the child will be placed .Anesthesia will maintained with sevoflurane at 2 3 vol % in 40% O2 in air to maintain a stable heart rate, blood pressure and respiratory rate (base line ± 20%). Paracetamol 15 mg/kg (Perfalgan® 100 ml vial UPSA France) and Dexamethasone 0.3 mg/kg will be administered IV to each child immediately after the induction of anesthesia. Lung ventilation will be controlled to maintain the end tidal carbon dioxide tension between 30 and 35 mmHg. Caudal block with 1.0 ml/kg 0.25% bupivacaine will be performed in all patients. Failure of caudal block will be defined as increase in heart rate and or mean arterial blood pressure (MAP) > 10% than pre-incisional value at the start of surgery. No opioid will be given; no propofol will be used during the procedure. The allocated children will be randomly assigned through computer-generated random numbers contained in sealed opaque envelopes to one of the three groups:

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Agitation

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
allocated children will be randomly assigned through computer-generated random numbers contained in sealed opaque envelopes to one of the three groups
Allocation
Randomized
Enrollment
126 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
nalbuphine
Arm Type
Experimental
Arm Description
0.1 mg/kg nalbuphine diluted in 10 ml I.V 10 minutes before the end of surgery
Arm Title
dexmedetomedine
Arm Type
Experimental
Arm Description
receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
Arm Title
saline
Arm Type
Placebo Comparator
Arm Description
receive a saline solution 10 min before the end of surgery
Intervention Type
Drug
Intervention Name(s)
Nalbuphine
Other Intervention Name(s)
nalophen
Intervention Description
will receive 0.1 mg/kg NAL diluted in 10 ml I.V 10 minutes before the end of surgery
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
Precedex
Intervention Description
will receive dexmedetomedine 0.5 mic/kg diluted in 10 ml I.V 10 minutes before the end of surgery
Intervention Type
Drug
Intervention Name(s)
normal Saline
Other Intervention Name(s)
saline
Intervention Description
will receive with a saline solution 10 min before the end of surgery
Primary Outcome Measure Information:
Title
Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) change
Description
Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) based on crying, facial expression, verbal statements, position of torso, touching of the wound and movement of legs will be used for post-operative pain assessment minimum score: 4 best maximum score: 13 worse
Time Frame
at 5, 10, 20 and 30 minutes post-operatively
Title
pediatric anesthesia emergence delirium (PAED) scale change
Description
pediatric anesthesia emergence delirium (PAED) scale, scale that define the child's behavior in the recovery room sleeping (best) awake, calm irritable, crying inconsolable crying (worse)
Time Frame
at 5, 10, 20 and 30 minutes post-operatively
Secondary Outcome Measure Information:
Title
The time of first postoperative analgesic dose
Description
in minutes
Time Frame
up to 24 hours post operative
Other Pre-specified Outcome Measures:
Title
occurrence of side effects in PACU like nausea and vomiting.
Description
incidence and severity
Time Frame
up to 24 hours post operative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ASA physical status I &II scheduled for elective lower abdominal surgical procedures (inguinal hernia repair and hypospadias) under general anesthesia Exclusion Criteria: history of hypersensitivity to the studied drug, refusal of the legal guardian chronic or acute intake of any sedative or analgesic drugs, Psychological& emotional disorder. Cognitive or developmental disorders. severely agitated child at induction of anesthesia Any neurological condition that would limit the patient's ability to communicate with or understand nursing personnel, Existing contraindications to caudal block such as coagulopathy, local and systemic infection. Failure of the caudal block.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
yasser M osman
Phone
+201006357996
Email
yasseralx@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
yasser M osman
Organizational Affiliation
Alexandria University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alexandria university
City
Alexandria
ZIP/Postal Code
0203
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamed M osman
Phone
01006357996
Email
yasseralx@hotmail.com
First Name & Middle Initial & Last Name & Degree
Yasser m osman, assist prof

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Nalbuphine Versus Dexmedetomidine for Prevention of Emergence Agitation in Pediatrics

We'll reach out to this number within 24 hrs